Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

San Diego company aiming to target glioblastoma with nanotechnology-based approach

By Brian Buntz | June 28, 2021

Glioblastoma

Intermediate magnification micrograph of a glioblastoma. HPS stain image courtesy of Wikimedia.

The emerging biopharmaceutical company Global Cancer Technology (GCT; San Diego) is developing a novel x-ray–activated modality for drug delivery to treat glioblastoma, which remains stubbornly difficult to treat.

GCT has a licensing agreement with the University of California, San Diego (UCSD) for a drug delivery platform that unites a nanocrystal to a prodrug that can be activated using radiosurgery. GCT has also acquired two patents for investigational drugs that can cross the blood-brain barrier. One is an inhibitor of phosphatidylinositol 3-kinase (PI3K), a type of enzyme involved in several cellular functions that facilitates rapid growth in glioblastoma. The other compound targets Vps34, a phosphatidylinositol 3-kinase. Both compounds modulate autophagy, a regenerative cellular process. According to UCSD researchers, autophagy yields amino acids that support tumor survival.

Karen NewellEarly research involving a collaboration between GCT and the Barrow Neurological Institute (Phoenix) indicates that inhibiting phosphatidylinositol 3-kinase enzymes may also alert the immune system to the presence of glioblastoma. “The results so far are preliminary but promising in that arena,” said M. Karen Newell-Rogers, a chief scientific consultant and advisor for the company.

But while PI3K inhibitors have shown promise in glioblastoma cultures, researchers have had less success using them in vivo given the challenge of homing in on the glioblastoma site. For that reason, GCT is using a nanotechnology-based drug delivery approach to target the tumor site.

Bob Proulx

Bob Proulx

“The goal is to concentrate that therapeutic effect, potentially use less of the drug and have a more efficacious effect because you’ve localized it to the site of the tumor,” said Bob Proulx, president and CEO of Imagion Biosystems. He is also an advisor to GCT.

To that end, GCT has licensed novel scintillator technology from UCSD. For context, a scintillator is a chemical entity that emits light when exposed to certain radiation spectra. GCT is experimenting with using a linker to conjoin a drug and nanoparticle. The linker is cleavable when a photon strikes it. “Once I know the particles are at the diseased tissue, I can hit them with a low dose of gamma radiation,” Proulx said. Then, using a radiosurgery tool such as a Gamma Knife, a surgeon can trigger the release of the drug. “That’s what makes this combination so unique,” Proulx added. It could combine a molecule that potentially targets a key growth mechanism in glioma and a mechanism for releasing it at the site where it is needed.

The approach is broadly similar to the use of antibody-drug conjugates (ADCs), small molecule drugs attached to an antibody intended to bind to and thus target cancer cells. One drawback to ADCs, however, is that “it’s often difficult to get antibody conjugates past the blood-brain barrier,” as Newell-Rogers explained.

Another potential problem with ADCs, though, relates to the bio-functionality of the antibody. If an ADC binds to a receptor on a cell, “your therapeutic payload may have been delivered, but it may be sitting there on the surface of the cell membrane,” Proulx said. This is because the ADC must be absorbed to have a therapeutic effect. “What’s novel about the GCT nano-scintillator particle is that it acts as a carrier,” Proulx added.

Once the drug reaches the tumor area, an external mechanism such as a Gamma Knife can activate it. “You can localize the gamma knife just to the place where you want the drug released,” Newell-Rogers said. “So you don’t have a lot of the toxicity issues that you have when you’re using a drug that could have activity all over the body.”


Filed Under: Drug Delivery, Drug Discovery
Tagged With: antibody-drug conjugates, blood-brain barrier, GCT, glioblastoma, Global Cancer Technology, Imagion Biosystems, phosphatidylinositol 3-kinase, scintillator, UCSD, x-ray activated therapy
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE